Filaggrin Mutation Status and Prevention of Atopic Dermatitis with Maternal Probiotic Supplementation

Area of Science:

• Allergy and Immunology
• Genetics
• Dermatology

Background:

• The World Allergy Organization suggests probiotics for preventing atopic dermatitis in high-risk infants.
• Filaggrin gene (FLG) mutations impair the skin barrier, increasing atopic dermatitis risk.
• The Probiotic in the Prevention of Allergy among Children in Trondheim (ProPACT) study explored probiotic efficacy.

Purpose of the Study:

• To investigate if maternal probiotic supplementation prevents atopic dermatitis in children with and without filaggrin gene (FLG) mutations.
• To analyze the association between FLG mutation status and atopic dermatitis risk.
• To determine if probiotic benefits differ based on FLG genotype.

Main Methods:

• DNA analysis of 228 children from the ProPACT study for three common FLG mutations (R501X, R2447X, 2282del4).
• Assessment of atopic dermatitis incidence in relation to maternal probiotic intake and child's FLG mutation status.
• Statistical analysis using risk ratios (RR) and confidence intervals (CI).

Main Results:

• Overall, 7% of children carried heterozygous FLG mutations, with each child having only one mutation type.
• FLG mutation status was not significantly associated with atopic dermatitis risk (RR=1.1; 95% CI 0.5 to 2.3).
• Maternal probiotics reduced atopic dermatitis risk (RR=0.6; 95% CI 0.4 to 0.9), with similar effects observed in children with FLG mutations (RR=0.6; 95% CI 0.1 to 4.1) and wildtype FLG (RR=0.6; 95% CI 0.4 to 0.9).

Conclusions:

• Maternal probiotic supplementation demonstrates a preventive effect against atopic dermatitis in infants.
• This preventive effect appears consistent across children with and without filaggrin gene (FLG) mutations.
• Larger, confirmatory studies are warranted to validate these findings and establish clinical recommendations.